1. Levodopa: back to the future

   • Mario Zappia
   • Carlo Colosimo
   • Werner Poewe

   EditorialNotes 16 November 2010 Pages: 247 - 248

2. A brief history of levodopa

   • Oleh Hornykiewicz

   OriginalPaper 16 November 2010 Pages: 249 - 252

3. Pharmacokinetics of levodopa

   • Manuela Contin
   • Paolo Martinelli

   OriginalPaper 16 November 2010 Pages: 253 - 261

   

4. Has drug therapy changed the natural history of Parkinson’s disease?

   • C. E. Clarke

   OriginalPaper 16 November 2010 Pages: 262 - 267

   

5. The clinical spectrum of levodopa-induced motor complications

   • E. Hametner
   • K. Seppi
   • W. Poewe

   OriginalPaper 16 November 2010 Pages: 268 - 275

   

6. Spectrum of addictions in Parkinson’s disease: from dopamine dysregulation syndrome to impulse control disorders

   • Roberto Ceravolo
   • Daniela Frosini
   • Ubaldo Bonuccelli

   OriginalPaper 16 November 2010 Pages: 276 - 283

7. The role of the long-duration response to levodopa in Parkinson’s disease

   • Mario Zappia
   • Alessandra Nicoletti

   OriginalPaper 16 November 2010 Pages: 284 - 287

8. Clinical problems in late-stage Parkinson’s disease

   • Oscar S. Gershanik

   OriginalPaper 16 November 2010 Pages: 288 - 291

   

9. Soluble and controlled-release preparations of levodopa: do we really need them?

   • Giovanni Fabbrini
   • Flavio Di Stasio
   • Alfredo Berardelli

   OriginalPaper 16 November 2010 Pages: 292 - 297

10. Dopaminergic therapy and subthalamic stimulation in Parkinson’s disease: a review of 5-year reports

    • Luigi M. Romito
    • Alberto Albanese

    OriginalPaper 16 November 2010 Pages: 298 - 304

11. Continuous dopaminergic delivery in Parkinson’s disease

    • Angelo Antonini
    • Giulia Ursino
    • Mauro Plebani

    OriginalPaper 16 November 2010 Pages: 305 - 308

12. Evidence-based initiation of dopaminergic therapy in Parkinson's disease

    • Janis M. Miyasaki

    OriginalPaper 16 November 2010 Pages: 309 - 313